NASDAQ
4.66USD
-0.05 (-1.06%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
675.6M
P/E
—
EPS
—
Beta
1.22
52W range
1.3-4.78
Day range
4.58–4.78
Open
4.68
Prev close
4.71
Volume
1.5M
Avg volume
1M
Dividend
0.00
IPO
2021-09-30
https://seekingalpha.com/article/4937678-omniab-lilly-style-partners-paying-attention-this-early-stage-biotech-stock · 8/18/2026+0.90
https://www.businesswire.com/news/home/20260424218280/en/OmniAb-to-Participate-in-Three-Upcoming-Investor-Conferences/ · 4/24/2026+0.10
https://www.zacks.com/stock/news/2878972/omniab-inc-oabi-reports-q4-loss-misses-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2878972 · 3/4/2026-0.80
https://www.businesswire.com/news/home/20251215018419/en/Launch-of-OmniUltra-Expands-OmniAb%E2%80%99s-Reach-into-New-Markets-and-Applications-Advances-Leadership-in-Antibody-Discovery-Technologies/ · 12/15/2025+0.80
https://www.businesswire.com/news/home/20251104539835/en/OmniAb-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights/ · 11/4/2025+0.60
https://www.zacks.com/stock/news/2779058/omniab-inc-oabi-expected-to-beat-earnings-estimates-should-you-buy?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_9-2779058 · 10/28/2025+0.40
https://www.businesswire.com/news/home/20251014283979/en/OmniAb-to-Report-Third-Quarter-2025-Financial-Results-on-November-4/ · 10/14/2025+0.00
https://www.benzinga.com/trading-ideas/long-ideas/25/08/47327996/top-3-health-care-stocks-youll-regret-missing-this-quarter-3 · 8/26/2025+0.50
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
